Intermediatebiotechnology

Genetic Testing

Overview

Genetic testing analyzes DNA for health information: diagnostic (confirming disease), carrier (reproductive risk), predictive/presymptomatic (Huntington's, BRCA), prenatal (NIPT, amniocentesis), newborn screening, and pharmacogenomic. Methods span single-gene tests to exome/genome sequencing. Results need careful interpretation: pathogenic vs VUS vs benign, penetrance, and the right not to know.

Learning objectives

  • List test types and their purposes
  • Explain NIPT vs invasive prenatal testing
  • Interpret variant classifications
  • Discuss direct-to-consumer testing limits

Test types

Diagnostic: does this patient have the suspected genetic condition? Carrier: are prospective parents carriers (CF, Tay-Sachs panels)? Predictive: will disease develop (Huntington's, BRCA1/2)? Prenatal: NIPT (cell-free fetal DNA screening) vs diagnostic amniocentesis/CVS. Newborn screening: biochemical/genetic panels for treatable conditions (PKU).

Screening vs diagnostic

Screening (NIPT) estimates risk; only diagnostic tests (amnio/CVS) confirm.

Methods

Single-gene/Sanger (targeted), gene panels (NGS, e.g., 100-gene cardiomyopathy panel), exome (~1-2% of genome, most coding disease variants), genome (everything, including interpretation burden). Chromosomal microarray detects CNVs. Choice balances yield, cost, and VUS burden.

Exome's sweet spot

Most Mendelian disease variants are coding: exome captures ~85% of diagnoses at a fraction of genome cost.

Interpreting results

ACMG classes: pathogenic, likely pathogenic, VUS (uncertain), likely benign, benign. VUS are common and anxiety-provoking; most are eventually downgraded. Penetrance and expressivity modulate risk; a pathogenic BRCA1 variant is not a cancer diagnosis.

VUS: the uncertain middle

Variants of uncertain significance should not drive irreversible medical decisions.

Direct-to-consumer

23andMe/AncestryDNA: genotyping chips (not sequencing) with limited health reports (FDA-authorized for a few variants: BRCA founder mutations, MUTYH). Limitations: incomplete variant coverage, no clinical interpretation, privacy concerns (data sales, law-enforcement access), and ancestry estimates that are statistical, not definitive.

Not clinical-grade

DTC results need clinical confirmation before medical action: false positives/negatives occur.

Key points

  • Types: diagnostic, carrier, predictive, prenatal, newborn, pharmacogenomic
  • NIPT screens; amniocentesis/CVS diagnose
  • ACMG classes: pathogenic -> benign; VUS needs caution
  • DTC tests are limited and need clinical confirmation

Common misconceptions

✗ Myth: A pathogenic variant means you will get the disease.

✓ Truth: Penetrance is often incomplete; risk is probabilistic, not certain (except fully penetrant like Huntington's).

✗ Myth: Genetic testing predicts everything about health.

✓ Truth: It covers genetic risk only; environment, lifestyle, and chance dominate most disease.

Practice questions

Q1. Amniocentesis differs from NIPT in being
  1. Earlier
  2. Diagnostic rather than screening
  3. Risk-free
  4. Cheaper
Answer: B.

Amnio/CVS analyze fetal cells directly: definitive but with small miscarriage risk.

Q2. A VUS result means the variant is
  1. Pathogenic
  2. Of uncertain significance: not actionable alone
  3. Benign
  4. Absent
Answer: B.

Uncertain significance: manage by phenotype and family data, not the VUS.

Q3. Newborn screening primarily targets
  1. Adult-onset diseases
  2. Treatable early-onset conditions like PKU
  3. Ancestry
  4. Athletic ability
Answer: B.

Screening is justified when early treatment changes outcomes.

Click a question to reveal the answer and explanation.

Frequently asked questions

What is non-invasive prenatal testing?

Sequencing cell-free fetal DNA in maternal blood to screen for trisomies 21/18/13 from ~10 weeks.

Should VUS guide surgery?

No: uncertain variants should not prompt prophylactic surgery; surveillance and family studies are appropriate.

What is GINA?

The US Genetic Information Nondiscrimination Act: bars health insurers/employers from using genetic data (not life/disability insurance).